Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures

NCT03459287 is registered in ClinicalTrials.gov with Cerus Corporation as lead sponsor.

NCT NCT03459287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03459287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures
Lead sponsor
Cerus Corporation
Phase
Phase 3
Overall status
Completed
Start date
December 5, 2018
Completion date
March 5, 2024
Enrollment
581 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

anemia